But is Rybrevant deep enough, and does ficerafusp use the right pivotal dose?
ApexOnco Front Page
Recent articles
2026’s first big oncology buyout is here.
Merck sees clinical setbacks in Keylynk-008, Leap-001 and Keyvibe-002.
Arvinas’s SERD appears to edge out Olema’s, but what’s the best CDK4/6 inhibitor for a phase 3 combination?
The company hopes that new edits could solve the relapse problem with allogeneic Car-Ts.
With inavolisib’s pivotal front-line win Roche reckons it can knock out Novartis’s Piqray.
Merus still hopes for a future for MCLA-129, but the doors are closing.
Jaypirca secures a CLL label, though plans to dominate will be tempered by this market’s fast-changing nature.